Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Viatris Launches Cystadrops, Its 1st Brand-Name Product in Japan
May 31, 2024
- Takeda’s cTTP Drug Adzynma Now Available in Japan
May 31, 2024
- Kaken to Transfer Bispecific IP to J&J as US Giant Nabs Asset
May 30, 2024
- AnGes/Vasomune’s ARDS Drug Gets Fast-Track Tag in US
May 30, 2024
- Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
- AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
May 29, 2024
- Boehringer’s Japan Pharma Sales Up 7% in 2023, Buoyed by Ofev, Jardiance
May 29, 2024
- Nippon Shinyaku Chief Defends Benefits of DMD Therapy after PIII Miss
May 29, 2024
- Novel Antibiotic Fetroja Now Available in Taiwan: Shionogi
May 29, 2024
- Cheplapharm to Take Over 2 More Brands from Clinigen in Japan
May 29, 2024
- Fuji Pharma Charts Its Future as Japan’s Leading Biosimilar Player, Stelara Follow-On as Pace Setter
May 28, 2024
- Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
May 28, 2024
- Daiichi Sankyo’s TROP2 ADC Shows OS Benefit in Subgroup of NSCLC
May 28, 2024
- Alzheimer’s Med Leqembi Approved in South Korea, Its 4th Market
May 28, 2024
- Sawai Recalls Antibiotic Cefdinir Manufactured by Choseido, 4 Other APIs
May 27, 2024
- MSD Chief Urges Further Reform around Spillovers; Japan Sales Up 11% in 2023
May 27, 2024
- Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
- AnGes to Roll Out Progeria Treatment Zokinvy on May 27
May 24, 2024
- Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
- AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…